27 results on '"Ziranu P"'
Search Results
2. 118P Immunosenescence and response to immunotherapy in elderly patients: A possible prognostic tool
3. Balance between the stem cell marker CD44 and CDX2 expression in colorectal cancer
4. 490P New horizons in metastatic colorectal cancer: Role of CD44 expression
5. 467P Monocyte to red blood cells ratio (MRR): an innovative haematologic prognostic parameter in FOLFIRI-aflibercept treated patients: A subgroup analysis from the DISTINCTIVE trial
6. 407P Neoadjuvant chemo-radiotherapy response in patients affected by mismatch repair deficient (dMMR) locally advanced rectal cancer
7. 417P Liquid biopsy driven anti-EGFR rechallenge in metastatic colorectal cancer
8. 459P Dynamic changes of pro-angiogenic factors during FOLFIRI-aflibercept treatment: Interim analysis of DISTINCTIVE trial
9. P-128 Influence of anti-diabetic medications on the outcomes of patients with pancreatic ductal adenocarcinoma and type 2 diabetes mellitus
10. PD-5 Retrospective comparative analysis of K-ras G12C vs other K-ras mutations in metastatic colorectal cancer patients treated with first-line chemotherapy doublet + bevacizumab
11. P-127 Lymphocyte to monocyte ratio as a prognostic factor in stage IV pancreatic ductal adenocarcinoma naive patients before gemcitabine-nab-paclitaxel chemotherapy
12. P-129 Concomitant RAS and BRAF mutations: Impact on overall survival and progression free survival in metastatic colorectal cancer patients
13. Correlation between p53 expression and clinical outcome in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan-cetuximab
14. Effectiveness of CA 19.9 in predicting prognosis in metastatic pancreatic cancer patients treated with nab-paclitaxel plus gemcitabine
15. A new prognostic score for biliary tract cancer: a multicenter experience
16. Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience
17. The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status - Trial in progress
18. P 53 abnormal expression might influence global outcome through EGFR modulation in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan cetuximab
19. Medical management of malignant bowel obstruction: our center experience
20. Fentanyl pectin nasal spray for breakthrough cancer pain treatment: a single center experience
21. Management of breakthrough cancer pain in patients with oral mucositis
22. The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild type colorectal cancer patients receiving irinotecan/cetuximab
23. Selection with a molecUlar PanEl foR Panitumumab EfficAcy in K-ras and n-ras wild type metastatic colorectal cancer (SUPER- PEAK)
24. REINVENT (REgorafenIb traNslational eValuation angiogENesis proTocol)
25. Selection with a molecUlar PanEl foR Panitumumab EfficAcy in K-ras and n-ras wild type metastatic colorectal cancer (SUPER- PEAK)
26. REINVENT (REgorafenIb traNslational eValuation angiogENesis proTocol)
27. Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Long-term results of a single-institutional experience.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.